PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: GenScript Corporation

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

GenScript Adds Stable Isotope Labeling and PEGylation Modifications to its Synthetic Peptide Offerings - International contract research organization (CRO) GenScript Corporation has added two additional peptide modification services, stable nonradioactive isotope labeling and PEGylation modification, to its existing peptide modification repertoire
GenScript Adds Stable Isotope Labeling and PEGylation Modifications to its Synthetic Peptide Offerings

 

NewswireToday - /newswire/ - Piscataway, NJ, United States, 2008/12/09 - International contract research organization (CRO) GenScript Corporation has added two additional peptide modification services, stable nonradioactive isotope labeling and PEGylation modification, to its existing peptide modification repertoire. 1548:HK

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Peptides labeled with stable isotopes such as 2H, 15N, and 13C are especially useful for NMR studies. However, their production is limited by the commercial availability of correspondingly labeled amino acids. In general, peptides labeled with stable isotopes at specific sites are usually difficult to obtain. GenScript representatives claim that this limitation can be removed by synthesizing customized peptides. GenScript's stable isotope labeling offerings include 2H, 15N, 13C, or both 15N and 13C labeling, which they can label any site of the peptide.

Synthetic peptide drugs tend to have low bioavailability and limited circulating half-life in vivo due to the interplay of factors such as enzymatic digestion, renal clearance, and low solubility, and yet they represent a category of potentially potent drugs. These problems can be partially circumvented by larger or more frequent doses, but this increases costs, decreases patient compliance, and causes other snags. GenScript claims that its PEGylation peptide modification services increase potential peptide drugs' therapeutic properties by enhancing their accessibility in vivo.

GenScript’s other peptide modification services include KLH, BSA, and ovalbumin conjugation, phosphorylation, amidation, acetylation, and MAP application as well as biotin and FITC labeling. Because customers may request multiple modifications to the same peptide, prices vary.

GenScript Corporation (genscript.com) is a reliable outsourcing partner providing a wide array of services to augment all stages of the drug discovery and biological reagent manufacturing processes, including high-quality gene synthesis and cloning, custom protein expression and purification, custom peptide synthesis and antibody development, custom stable cell line development, and a wide selection of biological reagents to life science researchers in industrial and academic settings. GenScript Corporation is headquartered in Piscataway, New Jersey.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: GenScript Corporation

 
 

Availability: All Metropolitan Area

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


GenScript Adds Stable Isotope Labeling and PEGylation Modifications to its Synthetic Peptide Offerings

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

GenScript Corporation | Peptide modification
Publisher Contact: Sally Wang - GenScript.com 
1-(877) 436-7274 info[.]genscript.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any GenScript Corporation securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From GenScript Corporation / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)